



The Nifty ended 0.67% down at 16301.85. It opened gap-down just below the trend line placed around and touched the low around 16140 towards finishing off with a spinning-top candle. Short-term chart pattern suggesting weakness likely to persist as long as it trades below 16650 levels. Intraday trading range likely to be 16100-16400.

On the Nifty hourly chart, extremely oversold leading indicators pointing towards intraday recovery, however, staying cautious on rise is advised. Intraday range likely to be 16100-16400.

Nifty patterns on multiple periods suggesting; it ended the day below the ascending trend line. Chart pattern suggesting negative bias likely to persist as long as it trades below 16650 levels. Downside supports are placed around 16150 and 16100 levels.

Nifty Crucial Supports & Resistances-

Supports- 16150, 16100 Resistances- 16400, 16500

Open Positional Calls-

T+14 INST POSITIONAL BUY-

| CASH Segment | HDFC BANK @ 1350-1330, TGT- 1430, Closing SL- below 1280

T+10 SELL-

| Futures Segment | AMBUJA Fut @ 379-380, TGT- 360, Closing SL- above 390

T+10 INST POSITIONAL BUY-

| Cash Segment | HPCL @ 271-270, TGT- 284, Closing SL- Below 263

T+10 INST POSITIONAL BUY-

| Cash Segment | BPCL @ 364-362, TGT- 383, Closing SL- Below 352

T+10 INST POSITIONAL SELL-

| Futures Segment | M&M Fut @ 900-905, TGT - 855, Closing SL- above 930

T+10 INST POSITIONAL BUY-

| Cash Segment | HUL @ 2140-2120, TGT- 2230, Closing SL- Below 2080

T+5 BUY-

| Cash Segment | MC DOWELL @ 815-810, TGT - 845, Closing SL- Below 795

Key Contents	Page No.
Result Update	4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks logged losses for second day, dragged by losses in metal, power, energy and consumer durables stocks. The Sensex and Nifty trimmed losses to close off day's low, aided by gains in information technology stocks.

Nifty index ended 0.67% lower at 16,302. The broader markets represented by the Nifty 500 Index ended 1.09% lower, ending at 13,992. Among the sectorial indices, Nifty IT was the only gainer, gaining by 0.05%. Nifty Energy was the only loser losing by 2.71%.

Power Grid was the top gainer, gaining by 2.83%, followed by HCL Technologies and Bajaj Auto which was gaining by 2.83% & 1.97% respectively. RIL was the top loser, losing by 3.91%, followed by Nestle India and Indusind Bank which fell by 2.89% & 2.81% respectively.

The Advance : Decline ratio stood at 581:1649

Market Turnover (In Crore) 09-05-2022

Name	Last	Previous
NSE Cash	55853.73	59820.17
NSE F&O	7664553.36	6152173.98
BSE Cash	4,183.67	4,373.78
BSE F&O	*NA	59.19

FII Derivatives Flow (In Crore) 06-05-2022*

Instrument	Purchase	Sale	Net
Index Future	3898.30	6388.56	2490.26
Index Option	496841.29	491799.68	5041.61
Stock Future	16486.00	16754.19	268.19
Stock Option	9666.20	9717.81	51.61

Institutional Flow (In Crore) 09-05-2022

Institution	Purchase	Sale	Net
FII	5342.44	8704.24	3361.8
DII	7729.78	4652.54	3077.24

*Data not updated till 5:50PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Power Grid	2.83	7.64	40589105	11847370
HCL Technologies	2.47	0.29	4207192	3203248
Bajaj Auto	1.97	4.31	502719	461237
Infosys	1.78	0.18	6832202	7088265
Divi'S Laboratories	1.57	6.09	262555	403850

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Tata Steel	2.45	1.48	5055297	8131373
Hero Motocorp	2.75	0.55	996952	1387406
Indusind Bank	2.81	9.08	3283626	5079350
Nestle India	2.89	9.96	115147	63832
Reliance Industries	3.91	9.75	8345649	7733828

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	54470.67	364.91	0.67	4.54	8.37	7.56	10.04
Nifty	16301.85	109.40	0.67	4.68	8.34	7.41	9.10
BSE M Cap	22692.18	437.43	1.89	7.07	10.32	7.87	10.11
BSE S Cap	26641.21	451.20	1.67	6.89	10.50	8.87	19.91
Nifty MC 100	28074.45	509.75	1.78	6.04	10.06	7.48	13.31
BSE Auto	23890.64	71.63	0.30	5.23	3.63	9.41	6.65
BSE Capgoods	26105.58	218.36	0.83	4.62	9.50	9.95	23.50
BSE FMCG	13502.24	214.29	1.56	4.12	4.31	0.68	5.95
BSE Metal	20270.37	409.97	1.98	6.39	13.73	4.11	0.38
BSE Oil&Gas	19018.16	393.50	2.03	2.46	3.78	4.13	21.69
BSE Healthcare	22780.00	136.19	0.59	6.41	8.74	7.17	5.28
BSE Power	4719.56	119.60	2.47	1.17	3.83	19.98	80.34
BSE Realty	3201.29	44.77	1.38	9.29	15.03	14.40	29.73
BSE ConsDur	38225.82	737.57	1.89	10.41	11.65	11.50	20.93
BSE Bank	39502.91	376.91	0.95	4.89	8.76	11.59	4.44
BSE IT	31077.66	28.99	0.09	2.85	12.94	10.73	16.02

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.18	0.05	1.73	6.71	17.80	63.82	101.67
UK	2.07	0.08	3.91	8.82	18.46	44.97	167.48
Brazil	5.82	0.18	3.25	2.21	10.17	17.96	51.77
Japan	0.25	0.00	1.64	7.36	7.83	18.10	181.82
Australia	3.56	0.09	2.68	9.29	20.21	69.26	112.08
India	7.47	0.02	0.23	1.22	4.93	9.74	24.16
Switzerland	1.04	0.02	2.17	15.37	44.49	268.68	602.91
Germany	1.18	0.05	4.33	22.00	67.04	457.08	649.30

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	77.46	0.53	0.69	1.22	1.94	3.43	5.31
USD Index	103.78	0.12	0.12	0.04	3.99	8.68	15.01
YUAN	6.73	0.06	0.89	1.76	5.31	5.41	4.61
GBP	1.24	0.00	0.03	1.12	5.20	8.74	12.51
EUR	1.05	0.00	0.10	0.31	3.16	7.75	13.10
YEN	131.07	0.51	0.39	0.69	4.35	11.86	16.98

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2718.00	74.00	2.80	13.06	32.26	58.85	14.61
Baltic Dirty	1162.00	20.00	1.69	7.26	30.71	70.38	91.43
SG Dubai HY	26.49	3.63	12.05	23.17	40.98	308.17	2497.06

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	32899.37	98.60	0.30	0.24	5.25	8.02	5.40
Nasdaq	12144.66	173.03	1.40	1.54	11.42	16.19	11.69
S&P 500	4123.34	23.53	0.57	0.21	8.13	10.11	2.58
FTSE100	7247.88	141.48	1.92	3.95	5.52	5.19	1.64
CAC40	6129.08	132.67	2.12	4.67	6.45	14.10	4.07
DAX	13444.54	238.09	1.74	3.61	5.93	13.21	12.75
Mexico IPC	49541.81	988.14	1.96	3.65	9.41	6.10	0.59
Brazil Bovespa	105134.7	0.00	0.00	2.54	11.15	6.51	13.85
Russian RTS	1088.02	31.90	2.85	3.72	0.74	29.11	31.03
Japan Nikkei	26319.34	684.22	2.53	1.43	2.47	4.97	10.84
Hang Seng	20001.96	791.44	3.81	1.35	8.55	19.44	30.09
Taiwan Index	16048.92	359.28	2.19	3.27	7.15	12.48	6.89
Shanghai Comp	3004.14	2.58	0.09	1.55	7.62	13.82	12.36
KOSPI	2610.81	33.70	1.27	3.13	3.32	5.81	19.65
Malaysia KLCI	1549.18	15.16	0.97	2.32	3.62	1.33	2.19
Jakarta Comp	6909.75	319.16	4.42	4.37	4.18	1.26	15.63
Philippine SE	6759.90	109.02	1.59	2.16	3.68	9.90	8.01
Thai Exch	1604.49	25.09	1.54	3.79	4.83	5.78	1.03

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	106.85	2.90	2.64	1.62	8.76	19.19	64.67
BRENT Crude	109.60	2.77	2.46	1.90	7.29	24.65	70.67
Natural Gas	7.94	0.09	1.16	6.35	25.08	95.91	207.66

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1860.32	24.47	1.30	0.20	4.53	1.42	1.54
Silver(\$/Ounce)	21.77	0.60	2.67	3.88	12.15	6.65	20.72
Aluminium	2809.99	74.26	2.57	6.82	17.75	9.31	12.87
Copper	9411.00	101.50	1.07	2.94	8.51	4.66	6.78
Zinc	3787.75	136.50	3.48	9.75	11.79	4.72	29.29
Lead	2222.50	43.50	1.92	1.44	7.40	1.44	0.87

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	210.60	0.15	0.07	2.45	9.05	18.05	31.17
Cotton	144.36	0.75	0.52	4.28	10.15	19.15	71.73
Sugar	18.88	0.28	1.46	0.16	6.86	6.07	17.49
Wheat	1117.75	9.25	0.83	5.90	5.62	42.21	56.82
Soybean	1608.25	13.75	0.85	2.25	3.58	1.13	17.01

UPL

UPL on reported 29 per cent jump in consolidated net profits for the quarter-ended March at Rs 1,379 crore compared to Rs 1,063 crore in the same quarter last year. The company said its EBITDA grew by 26 per cent YoY to Rs 3,591 crore as against Rs 2,839 crore in Q4 FY21. Improved realizations, backward integration linkages for key products and effective supply chain management aided in delivering higher EBITDA margins – up 46 bps to 22.6 per cent. Q4 revenue witnessed “robust growth” of 24 per cent year-on-year (YoY) to reach Rs 15,860 crore, led by better product realizations (+19 per cent), higher volumes (+3 per cent) and currency impact (+2 per cent). The company had reported revenue at Rs 12,797 crore in Q4 of last year.

Central Bank of India

Net profit of Central Bank of India reported to Rs 310.31 crore in the quarter ended March 2022 as against net loss of Rs 1349.21 crore during the previous quarter ended March 2021. Total Operating Income rose 18.64% to Rs 5787.33 crore in the quarter ended March 2022 as against Rs 4878.02 crore during the previous quarter ended March 2021. For the full year, net profit reported to Rs 1044.83 crore in the year ended March 2022 as against net loss of Rs 887.58 crore during the previous year ended March 2021. Total Operating Income rose 0.31% to Rs 22801.65 crore in the year ended March 2022 as against Rs 22730.23 crore during the previous year ended March 2021.

Suven Pharma

Suven Pharmaceuticals on Monday said its consolidated profit after tax has increased by 11 per cent to Rs 92 crore for the fourth quarter ended March. The company had reported a profit after tax (PAT) of Rs 83 crore in the January-March quarter of 2020-21 fiscal. Revenue from operations rose to Rs 364 crore in the fourth quarter as against Rs 259 crore in the same period of previous fiscal. For the year ended March 31, 2022, the drug firm reported a PAT of Rs 454 crore as compared with Rs 362 crore in FY21. Revenue from operations rose to Rs 1,320 crore as against Rs 1,010 crore in the 2020-21 financial year.

PVR

PVR Ltd reported narrowing of its consolidated net loss to Rs 105.49 crore for the fourth quarter ended in March 2022. The company had posted a net loss of Rs 289.21 crore in the January-March quarter a year ago. Its revenue from operations rose by nearly three-fold to Rs 537.14 crore during the quarter under review as against Rs 181.46 crore in the corresponding quarter last fiscal. Its total expenses were at Rs 731.17 crore, up 43.91 per cent in Q4/FY 2021-22 as against Rs 508.07 crore in the year-ago quarter.

BASF India

Net profit of BASF India rose 168.50% to Rs 149.85 crore in the quarter ended March 2022 as against Rs 55.81 crore during the previous quarter ended March 2021. Sales rose 20.89% to Rs 3383.34 crore in the quarter ended March 2022 as against Rs 2798.65 crore during the previous quarter ended March 2021. For the full year, net profit rose 7.64% to Rs 594.84 crore in the year ended March 2022 as against Rs 552.61 crore during the previous year ended March 2021. Sales rose 37.08% to Rs 13082.23 crore in the year ended March 2022 as against Rs 9543.18 crore during the previous year ended March 2021.

Mold-Tek Packaging

Mold-Tek Packaging Q4 FY2021-22 consolidated PAT up QoQ at Rs. 17.31 crores. The company has reported total income of Rs. 179 crores during the period ended March 31, 2022 as compared to Rs. 160 crores during the period ended December 31, 2021. The company has posted net profit / (loss) of Rs. 17.3166 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs. 16.6643 crores for the period ended December 31, 2021. The company has reported EPS of Rs. 5.41 for the period ended March 31, 2022 as compared to Rs. 5.39 for the period ended December 31, 2021.

Borosil Renewables

Borosil Renewables' March 2022 quarter net profit fell to Rs 46.38 crore against Rs 66.87 crore in the year-ago period, mainly due to lower revenues. The total income declined to Rs 182.33 crore in the quarter from Rs 196.90 crore a year ago. Its net profit rose to Rs 165.84 crore in 2021-22 from Rs 89.64 crore in 2020-21. For FY22, the total income increased to Rs 664.73 crore from Rs 507.63 crore in the preceding fiscal.

Aarti Drugs

Aarti Drugs reported 7.1% rise in consolidated net profit to Rs 55.34 crore in Q4 FY22 from Rs 51.65 crore posted in Q4 FY21. The company's consolidated net sales jumped 38.4% to Rs 694.27 crore in Q4 FY22 compared to Rs 501.75 in Q4 FY21. Profit before tax rose 8% year on year to Rs 70.5 crore in Q4 FY22. Total expenses were up by 43.2% year on year to Rs 626.73 crore in Q4 FY22. Cost of raw materials consumed stood at Rs 471.08 crore, rising by 56.3% year on year in the quarter ended 31 March 2022. On full year basis, the pharma company posted a 26.9% decline in net profit to Rs 205.04 crore despite a 15.5% increase in net sales to Rs 2,488.65 crore in FY22 over FY21.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Laurus Labs Ltd	Cash dividend of INR1.20 effective 10-05-2022
Elantas Beck India Ltd	Corporate meeting effective 10-05-2022
Yash Pakka Ltd	Corporate meeting effective 10-05-2022
Sarla Performance Fibers Ltd	Corporate meeting effective 10-05-2022
Shukra Bullions Ltd	Corporate meeting effective 10-05-2022
Avro India Ltd	Corporate meeting effective 10-05-2022
Shukra Bullions Ltd	Corporate meeting effective 10-05-2022
Shukra Jewellery Ltd	Corporate meeting effective 10-05-2022
Tree House Education and Accessories Ltd	Corporate meeting effective 10-05-2022
Ashok Alco Chem Ltd	Corporate meeting effective 10-05-2022

Domestic Events

- No events

Global Events

- Japan Foreign Exchange Reserve for April 2022.
- Euro Area ZEW Economic Sentiment Index for May 2022.

Analyst Certification:

We /I, Jaydeb Dey and Shreyansh N. Mehta Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
